Satellos Bioscience (MSLE) EPS (Basic) (2025 - 2026)
Satellos Bioscience (MSLE) posted quarterly EPS (Basic) of -$0.53 for Q1 2026, down 220.91% year-over-year from $0.44 in Q1 2025, and down 220.91% quarter-over-quarter from $0.44 in Q1 2025.
Satellos Bioscience (MSLE) EPS (Basic) (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has reported EPS (Basic) for 2 consecutive years, with -$0.53 the latest figure, recorded in Q1 2026.
- In Q1 2026, EPS (Basic) fell 220.91% year-over-year to -$0.53; the TTM figure through Mar 2026 stood at -$0.2 (changed N/A YoY), while the FY2025 annual figure was -$1.71, up 19.04% from the prior year.
- EPS (Basic) declined to -$0.53 in Q1 2026 per MSLE's latest filing, from $0.44 in the prior quarter.
- Across five years, EPS (Basic) topped out at $0.44 in Q1 2025 and bottomed at -$0.53 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.23 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.06 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 0.18 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -0.72 |
| 10 | Satellos Bioscience | 208.31 Mn | 208.31 Mn | - | -0.56 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.53 |
| Mar 31, 2025 | 0.44 |